How To Get 270 Approvals At Once? – Stealth's Rare Disease Strategy
This article was originally published in The Pink Sheet Daily
With FDA’s blessing, Stealth BioTherapeutics is working toward a pivotal trial that would address an underlying cause, mitochondrial myopathy, of roughly 270 very rare diseases, potentially leading to an aggregate approval in all of those unmet medical needs.
You may also be interested in...
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.
From the latest COVID-19 advances to the emergence of game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.